Thalidomide: From Tragedy to Targeted Myeloma Therapy

Thalidomide's history is a landmark in pharmacovigilance; its modern use is strictly controlled.

Historical Tragedy (1957–1961)

• Marketed as sedative/anti-nausea for pregnancy.
• Caused >10,000 cases of phocomelia (limb malformations) worldwide.
• Withdrawn 1961; led to modern drug approval rigor (Kefauver-Harris Amendment, 1962).

Mechanism in Multiple Myeloma

• Anti-angiogenic: Inhibits VEGF/FGF → blocks tumor neovascularization.
• Immunomodulatory: Enhances T/NK cell activity; inhibits TNF-α.
• Direct tumoricidal: Induces apoptosis in myeloma cells.

Current Indications

• Newly diagnosed multiple myeloma (with dexamethasone ± bortezomib, lenalidomide, daratumumab).
• Relapsed/refractory myeloma.
• Erythema nodosum leprosum (ENL).

Dosing & Monitoring

• Typical: 200–400 mg PO daily at bedtime (sedation).
• Renal adjustment: CrCl <30 → reduce dose.
• Monitor: Peripheral neuropathy (q visit), VTE risk (prophylaxis often needed), constipation, bradycardia, rash, LFTs, thyroid.

REMS Program (Mandatory)

• Zero tolerance for fetal exposure.
• Females of reproductive potential: 2 negative pregnancy tests before start, monthly during, 4 wks after. Two contraception methods.
• Males: Condom use (semen contains drug); no sperm donation.
• Prescriber, pharmacy, patient all certified.

Key Interactions

• CNS depressants (↑ sedation): opioids, benzos, alcohol.
• Warfarin (↑ INR unpredictably).
• Anticonvulsants (carbamazepine, phenytoin ↓ thalidomide levels).
• Azole antifungals (↑ thalidomide levels).

Thalidomide is a potent myeloma drug—but its teratogenicity demands absolute vigilance.